PNC Financial Services Group
CMPX icon

PNC Financial Services Group’s Compass Therapeutics CMPX Stock Holding History

PNC Financial Services Group’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Sell
10,939
-99
-0.9% -$292 ﹤0.01% 3702
2026
Q1 		$58.4K Buy
11,038
+10,625
+2,573% +$61.3K ﹤0.01% 3132
2025
Q4 		$2.22K Sell
413
-5,409
-93% -$25K ﹤0.01% 4502
2025
Q3 		$20.4K Buy
5,822
+485
+9% +$1.53K ﹤0.01% 3634
2025
Q2 		$13.9K Buy
5,337
+337
+7% +$695 ﹤0.01% 3735
2025
Q1 		$9.5K Buy
5,000
+4,995
+99,900% +$13.3K ﹤0.01% 3845
2024
Q4 		$7 Buy
+5
New +$8 ﹤0.01% 4773

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PNC Financial Services Group's CMPX Position: Q2 2026 in Review

PNC Financial Services Group reduced its Compass Therapeutics (CMPX) stake by 0.9% in Q2 2026, selling an estimated $292 and leaving 10,939 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #3702.

PNC Financial Services Group first reported a position in CMPX in Q4 2024 and has held it in 7 quarters since. The position peaked at $58.4K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • PNC Financial Services Group held 10,939 shares of Compass Therapeutics worth $24K as of Q2 2026.
  • PNC Financial Services Group sold 99 Compass Therapeutics shares in Q2 2026, an estimated $292.
  • Compass Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q2 2026, its #3702 holding.
  • PNC Financial Services Group first reported a position in Compass Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • PNC Financial Services Group's Compass Therapeutics position peaked at $58.4K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on PNC Financial Services Group's 13F filing for Q2 2026, filed 7 Aug 2026.